Novo Nordisk Sees Modest Profit Increase Amidst Strong Sales Growth
Danish pharmaceutical giant Novo Nordisk, known for its popular diabetes and weight-loss drugs Ozempic and Wegovy, reported a modest rise in net profit for the second quarter of 2024. The company, which holds the title of Europe’s most valuable firm, announced that its profit after tax reached 20 billion Danish kroner ($2.7 billion) from April …
Read more